弊社は、バイオ革命によって急速に発展し始めている再生医療分野において、体性幹細胞再生医薬品/iPSC再生医薬品の研究開発を行っているバイオベンチャーです。2015年6月には東証マザーズに上場。再生・細胞医薬品の開発・製造を世界で先駆けて取り組み、病で苦しむ患者さんに治療法を提供し希望を届けることを目標としています。 Our company is a bio venture which is doing R & D of somatic stem cell regenerating medicine / iPSC regenerating medicine in the regenerative medicine field which is rapidly developing by the bio-revolution. We were listed on TSE Mothers in June 2015. Our long-term object is to deliver hope to patients suffering from illness by providing treatment methods by pioneering the development and manufacture of regeneration and cellular medicines worldwide.
View Top Employees from 株式会社ヘリオス| Website | http://www.healios.co.jp |
| Ticker | TYO:4593 |
| Revenue | $7 million |
| Employees | 26 (21 on RocketReach) |
| Founded | 2011 |
| Address | Yurakucho Denki Building North Tower 19th floor 1-7-1 Yurakucho Chiyoda-ku, Tokyo 100-0006, JP |
| Phone | +81 3-5777-8308 |
| Technologies |
JavaScript,
HTML,
Google Analytics
+2 more
(view full list)
|
| Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Health Care, Medical |
| Web Rank | 3 Million |
| Keywords | ヘリオス, 4593, 再生医療 脳梗塞 治験, 医療再生, 再生医療とは |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 541713 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies |
Looking for a particular 株式会社ヘリオス employee's phone or email?
株式会社ヘリオス Questions
The 株式会社ヘリオス annual revenue was $7 million in 2024.
21 people are employed at 株式会社ヘリオス.
The NAICS codes for 株式会社ヘリオス are [541, 541713, 54171, 54, 5417].
The SIC codes for 株式会社ヘリオス are [873, 87].
Top 株式会社ヘリオス Employees
-
35+
-
1
Related Companies
